MLH1 and colorectal carcinoma: Corresponding cumulative incidences for CRC were 28.0% (95% CI (23.3–32.7)) versus 23.8% (95% CI (14.6–33.0)) for path_MLH1 carriers and 18.1% (95% CI (13.3–22.9)) versus 15.1% (95% CI (6.4–23.8)) for path_MSH2 carriers with truncating or missense/aberrant splicing variants, respectively.